Topic · CAR-T cell therapy research
Most cited papers in CAR-T cell therapy research
What are the most cited papers in CAR-T cell therapy research?
The most cited paper in CAR-T cell therapy research is "PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer" (Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al., 2016), with 30,915 citations. Next come "The blockade of immune checkpoints in cancer immunotherapy" (14,033) and "Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer" (12,842).
Showing 50 of 100 papers. Every paper with more than 1,918 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al. · Breast Care | 2016 | 30,915 |
| 2 | The blockade of immune checkpoints in cancer immunotherapy Drew M. Pardoll · Nature reviews. Cancer | 22 Mar 2012 | 14,033 |
| 3 | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne Louise Topalian et al. · New England Journal of Medicine | 14 Jun 2012 | 12,842 |
| 4 | Control of Regulatory T Cell Development by the Transcription Factor Foxp3 Shohei Hori, Takashi Nomura, Shimon Sakaguchi · Science | 13 Feb 2003 | 8,213 |
| 5 | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie Renee Brahmer et al. · New England Journal of Medicine | 14 Jun 2012 | 8,100 |
| 6 | Oncology Meets Immunology: The Cancer-Immunity Cycle Daniel S. Chen, Ira Mellman · Immunity | Jul 2013 | 7,122 |
| 7 | Cancer immunotherapy using checkpoint blockade Antoni Ribas, Jedd D. Wolchok · Science | 22 Mar 2018 | 6,951 |
| 8 | PD-1 blockade induces responses by inhibiting adaptive immune resistance Paul C. Tumeh et al. · Nature | 25 Nov 2014 | 6,760 |
| 9 | TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells Taiwen Li, Jing‐Yu Fan, Binbin Wang et al. · Cancer Research | 31 Oct 2017 | 6,637 |
| 10 | Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Sattva Swarup Neelapu et al. · New England Journal of Medicine | 10 Dec 2017 | 6,098 |
| 11 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia Shannon L. Maude et al. · New England Journal of Medicine | 31 Jan 2018 | 5,818 |
| 12 | CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma Bertrand Coiffier, Éric Lepage, Josette Brière et al. · New England Journal of Medicine | 24 Jan 2002 | 5,630 |
| 13 | Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw et al. · New England Journal of Medicine | 15 Oct 2014 | 5,489 |
| 14 | Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq Itay Tirosh et al. · Science | 7 Apr 2016 | 5,440 |
| 15 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Roy S. Herbst et al. · Nature | 25 Nov 2014 | 5,353 |
| 16 | The future of immune checkpoint therapy Padmanee Sharma, James Patrick Allison · Science | 2 Apr 2015 | 4,925 |
| 17 | Neoantigens in cancer immunotherapy Ton N. Schumacher, Robert D. Schreiber · Science | 2 Apr 2015 | 4,884 |
| 18 | Revised Response Criteria for Malignant Lymphoma Bruce D. Cheson, Beate Pfistner, Malik Eid Juweid et al. · Journal of Clinical Oncology | 22 Jan 2007 | 4,468 |
| 19 | Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Christine P. Hans · Blood | 22 Sep 2003 | 4,323 |
| 20 | A guide to cancer immunotherapy: from T cell basic science to clinical practice Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo · Nature reviews. Immunology | 20 May 2020 | 4,257 |
| 21 | Nivolumab plus Ipilimumab in Advanced Melanoma Jedd D. Wolchok et al. · New England Journal of Medicine | 2 Jun 2013 | 4,257 |
| 22 | Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma Stephen J. Schuster et al. · New England Journal of Medicine | Dec 2018 | 4,157 |
| 23 | Restoring function in exhausted CD8 T cells during chronic viral infection Daniel L. Barber, E. John Wherry, David Masopust et al. · Nature | 28 Dec 2005 | 4,031 |
| 24 | IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade Mark Ayers, Jared K. Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation | 25 Jun 2017 | 3,983 |
| 25 | Cancer immunotherapy comes of age Ira Mellman, George Coukos, Glenn Dranoff · Nature | 20 Dec 2011 | 3,936 |
| 26 | The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma Andreas Rosenwald et al. · New England Journal of Medicine | 20 Jun 2002 | 3,883 |
| 27 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma James Larkin et al. · New England Journal of Medicine | 28 Sep 2019 | 3,784 |
| 28 | ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells Daniel W. Lee et al. · Transplantation and Cellular Therapy | 25 Dec 2018 | 3,663 |
| 29 | A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis Hervé Groux, Anne O’Garra, Mike Bigler et al. · Nature | Oct 1997 | 3,601 |
| 30 | Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia David L. Porter, Bruce L. Levine, Michael D. Kalos et al. · New England Journal of Medicine | 10 Aug 2011 | 3,584 |
| 31 | LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 S. Hacein-Bey-Abina et al. · Science | 16 Oct 2003 | 3,582 |
| 32 | The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity Noa Stanietsky, Hrvoje Šimić, Jurica Arapović et al. · Proceedings of the National Academy of Sciences | 7 Oct 2009 | 3,551 |
| 33 | Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia Stephan A. Grupp, Michael D. Kalos, David Maxwell Barrett et al. · New England Journal of Medicine | 25 Mar 2013 | 3,532 |
| 34 | T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity Steven A. Gillis, Mary M. Ferm, Winny Ou et al. · The Journal of Immunology | Jun 1978 | 3,300 |
| 35 | Cytokine Storm David C. Fajgenbaum, Carl H. June · New England Journal of Medicine | 2 Dec 2020 | 3,277 |
| 36 | CAR T cell immunotherapy for human cancer Carl H. June, Roddy S. O’Connor, Omkar Uday Kawalekar et al. · Science | 22 Mar 2018 | 3,253 |
| 37 | A simplified system for generating recombinant adenoviruses Tong‐Chuan He, Shibin Zhou, Luís Teixeira da Costa et al. · Proceedings of the National Academy of Sciences | 3 Mar 1998 | 3,244 |
| 38 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade Nicholas McGranahan et al. · Science | 3 Mar 2016 | 3,177 |
| 39 | The Immunobiology of Cancer Immunosurveillance and Immunoediting Gavin P. Dunn, Lloyd J. Old, Robert D. Schreiber · Immunity | Aug 2004 | 3,034 |
| 40 | Genomic correlates of response to CTLA-4 blockade in metastatic melanoma Eliezer M. Van Allen et al. · Science | 11 Sep 2015 | 3,022 |
| 41 | Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Julie Renee Brahmer, Charles G. Drake, IRA S. WOLLNER et al. · Journal of Clinical Oncology | Jun 2010 | 2,970 |
| 42 | T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson et al. · The Lancet | 13 Oct 2014 | 2,968 |
| 43 | CAR-T cell therapy: current limitations and potential strategies Robert C. Sterner, Rosalie M. Sterner, Rosalie M. Sterner et al. · Blood Cancer Journal | 6 Apr 2021 | 2,920 |
| 44 | The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications Yuanyuan Zhang, Zemin Zhang · Cellular and Molecular Immunology | Jul 2020 | 2,895 |
| 45 | Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Glen Dranoff, Elizabeth M. Jaffee, Allison Lazenby et al. · Proceedings of the National Academy of Sciences | 15 Apr 1993 | 2,863 |
| 46 | Current concepts in the diagnosis and management of cytokine release syndrome Daniel W. Lee, Rebecca Alice Gardner, David Porter et al. · Blood | 30 May 2014 | 2,849 |
| 47 | B cells and tertiary lymphoid structures promote immunotherapy response Beth Ann Helmink et al. · Nature | 15 Jan 2020 | 2,809 |
| 48 | Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Peter Joseph McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology | Aug 1998 | 2,774 |
| 49 | A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone Steven A. Rosenberg, Michael T. Lotze, Linda Mesler Muul et al. · New England Journal of Medicine | 9 Apr 1987 | 2,769 |
| 50 | Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia Jae H. Park, Isabelle Rivière, Mithat Gönen et al. · New England Journal of Medicine | 31 Jan 2018 | 2,736 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.